195 related articles for article (PubMed ID: 37542550)
21. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
Ma LX; Espin-Garcia O; Bedard PL; Stockley T; Prince R; Mete O; Krzyzanowska MK
Thyroid; 2022 Jun; 32(6):657-666. PubMed ID: 35262412
[No Abstract] [Full Text] [Related]
22. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
23. Genomic Profiling of Sarcomas: A Promising Weapon in the Therapeutic Arsenal.
Lopes-Brás R; Lopez-Presa D; Esperança-Martins M; Melo-Alvim C; Gallego L; Costa L; Fernandes I
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430703
[TBL] [Abstract][Full Text] [Related]
24. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
Groisberg R; Hong DS; Roszik J; Janku F; Tsimberidou AM; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer Ther; 2018 Jul; 17(7):1595-1601. PubMed ID: 29654067
[TBL] [Abstract][Full Text] [Related]
25. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
[TBL] [Abstract][Full Text] [Related]
27. Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas.
Juan Ribelles A; Gargallo P; Berlanga P; Segura V; Yáñez Y; Juan B; Salom M; Llavador M; Font de Mora J; Castel V; Cañete A
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33916788
[No Abstract] [Full Text] [Related]
28. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.
Groisberg R; Roszik J; Conley A; Patel SR; Subbiah V
Curr Oncol Rep; 2017 Oct; 19(12):78. PubMed ID: 29030741
[TBL] [Abstract][Full Text] [Related]
29. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.
VanderWalde A; Grothey A; Vaena D; Vidal G; ElNaggar A; Bufalino G; Schwartzberg L
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33260805
[TBL] [Abstract][Full Text] [Related]
30. Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital.
Pinet S; Durand S; Perani A; Darnaud L; Amadjikpe F; Yon M; Darbas T; Vergnenegre A; Egenod T; Simonneau Y; Le Brun-Ly V; Pestre J; Venat L; Thuillier F; Chaunavel A; Duchesne M; Fermeaux V; Guyot A; Lacorre S; Bessette B; Lalloué F; Durand K; Deluche E
Front Oncol; 2023; 13():1104659. PubMed ID: 36923436
[TBL] [Abstract][Full Text] [Related]
31. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
32. The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours.
El Helali A; Lam TC; Ko EY; Shih DJH; Chan CK; Wong CHL; Wong JWH; Cheung LWT; Lau JKS; Liu APY; Chan ASY; Loong HH; Lam STS; Chan GC; Lee VHF; Yuen KK; Ng WT; Lee AWM; Ma ESK
Lancet Reg Health West Pac; 2023 Jul; 36():100775. PubMed ID: 37547050
[TBL] [Abstract][Full Text] [Related]
33. A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich.
Zhang D; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Greif PA; Ziemann F; Beyer G; Roessler D; Goni E; Renz B; D'Haese JG; Kunz WG; Seidensticker M; Corradini S; Niyazi M; Ormanns S; Kumbrink J; Jung A; Mock A; Rudelius M; Klauschen F; Werner J; Mayerle J; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
Target Oncol; 2023 Sep; 18(5):767-776. PubMed ID: 37594677
[TBL] [Abstract][Full Text] [Related]
34. Lessons learned: the first consecutive 1000 patients of the CCCMunich
Heinrich K; Miller-Phillips L; Ziemann F; Hasselmann K; Rühlmann K; Flach M; Biro D; von Bergwelt-Baildon M; Holch J; Herold T; von Baumgarten L; Greif PA; Jeremias I; Wuerstlein R; Casuscelli J; Spitzweg C; Seidensticker M; Renz B; Corradini S; Baumeister P; Goni E; Tufman A; Jung A; Kumbrink J; Kirchner T; Klauschen F; Metzeler KH; Heinemann V; Westphalen CB
J Cancer Res Clin Oncol; 2023 May; 149(5):1905-1915. PubMed ID: 35796778
[TBL] [Abstract][Full Text] [Related]
35. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
[TBL] [Abstract][Full Text] [Related]
36. Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?
Italiano A
Curr Treat Options Oncol; 2018 Dec; 19(12):78. PubMed ID: 30523434
[TBL] [Abstract][Full Text] [Related]
37. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
[TBL] [Abstract][Full Text] [Related]
38. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital.
Teuwen LA; Roets E; D'Hoore P; Pauwels P; Prenen H
Diagnostics (Basel); 2023 May; 13(9):. PubMed ID: 37175010
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]